Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 20 Animal Health Companies in the World

In this article, we will take a detailed look at the Top 20 Animal Health Companies in the World with insights into the revenue generated in 2022. For a quick overview of the top 5 animal health companies, read our article Top 5 Animal Health Companies in the World.

The animal health industry is in solid shape for continued growth despite global economic downturns in 2020 due to COVID-19. Medium to long-term livestock and companion animal market trends are essential in determining future market behaviors in the related animal health industry.

The global animal health market is expected to grow at a CAGR of 3.36% from 2023 to 2028, reaching US$45.2 billion by 2028. This growth is driven by several factors, including increasing number of pet owners and their desire for high-quality veterinary care, rising awareness of zoonotic diseases, and numerous technological advancements.

According to Bloomberg, the pet economy is expected to grow more than 50% in coming years, driven by spending on sophisticated drugs and treatments and pampering. The pandemic pet boom added 5 million new pets to U.S. households, a 4% increase. This surge in pet ownership is fueling the growth of the animal healthcare industry. Pet owners are increasingly willing to invest in their pets’ health and well-being, leading to demand for more sophisticated drugs and treatments.

A Look into the Animal Healthcare Industry

Zoetis Inc. (NYSE: ZTS), the world’s largest producer of medicine and vaccinations for pets and livestock, reported a solid second quarter of 2023. The company saw a 9% operational revenue growth and 12% operational adjusted net income growth. This was driven by a diverse portfolio across markets and species. Segment growth was more balanced this quarter, with 11% active growth internationally and 7% growth in the U.S. operations. The first half has primarily been as expected, with 6% operational revenue growth. However, Zoetis Inc. (NYSE: ZTS) expects more substantial growth in the year’s second half, especially in its U.S. companion animal business.

Additionally, in livestock, which has grown 8% year-to-date on an operational basis, Zoetis anticipates unfavorable comparisons in the second half due to the timing of price decreases in Jackson in the U.S. last year and resumption of supply of several products after outages in the first half of 2022.

Elanco Animal Health, Inc. (NYSE:ELAN), a $4.5 billion market cap company, posted a loss of $78 million in its most recent financial year. However, analysts expect Elanco Animal Health, Inc. (NYSE:ELAN) to reach the break-even point in 2024 after incurring a final loss in 2023. This is good news for investors, as it suggests that Elanco Animal Health, Inc. (NYSE:ELAN) is on the right track.

Importance of R&D Investments in the Animal Healthcare Industry

Two leaders in the animal health sector, Kathy Turner of IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Rob Kelly of Zoetis Inc. (NYSE:ZTS), believe that companies should continue to invest in R&D during the current economic downturn. They acknowledge that it will be difficult for all firms to maintain the same level of pre-COVID-19 spending, but they argue that R&D is essential to the industry’s long-term success. European animal healthcare companies spend 8% of revenue on R&D, investing over €600 million annually in new product development.

didesign021/Shutterstock.com

Methodology

To rank the top 20 animal health companies in the world, we sourced data from Pharma Shots and Fierce Pharma. We have mentioned annual revenue with each company.

Top 20 Animal Health Companies in the World

  1. Immucell Corp (NASDAQ:ICCC)

Annual Revenue in 2022 (Million USD): 19

ImmuCell Corp (NASDAQ:ICCC), an animal health company, develops, manufactures, and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. However, the company’s earnings have declined by an average of 10.5% per year over the past five years.

  1. Dechra

Annual Revenue in 2022 (Million USD):  827

Swedish investment firm E.Q.T. proposes acquiring Dechra Pharmaceuticals in an all-cash deal worth £4.6 billion ($5 billion). This represents a premium of 51% on Dechra’s closing stock price, making it one of the most significant potential UK take-private deals this year.

  1. Animal Care Group Plc

Annual Revenue in 2022 (Million USD): 86.9 

Animal Care Group Plc, a UK-based international veterinary pharmaceutical company, develops and markets prescription and over-the-counter products that improve animal health and well-being. The company operates in three categories: companion animals, equine and other, and production animals. Its essential product is Daxocox, a differentiated COX-2 inhibitor for treating chronic pain in dogs.

  1. SeQuent

Annual Revenue in 2022 (Million USD): 170

SeQuent has rapidly become India’s leading animal health company, establishing a global niche with its unique business model. The company has grown from acquiring and integrating businesses in key international markets to successfully scaling and consolidating its operations.

  1. KRKA

Annual Revenue in 2022 (Million USD): 1.7

KRKA d.d. shareholders have enjoyed a total shareholder return (TSR) of 30% over the past year, including dividends. This exceeds the company’s five-year average T.S.R. of 21%, suggesting that investor sentiment is positive.

  1. Vibrac

Annual Revenue in 2022 (Million USD): 195.3

Virbac will continue accelerating in 2023 on two key dimensions: R&D and capital expenditures. Virbac plans to boost its R&D investment to around 8.5% of revenues in 2023 and increase its capital expenditure investments to approximately €100 million. This will help the company prepare for the future, accompany its growth, and increase its medium-term productivity.

  1. Heska Corp (NASDAQ:HSKA)

Annual Revenue in 2022 (Million USD): 257 

According to the Q4 2022 Heska Corp (NASDAQ:HSKA) earnings call, the company had a strong Q4 in 2022, with solid execution, significant investment, and preparation for good momentum entering 2023. The company continued to gain market share, significantly improve gross margin, and deliver 15% to 18% growth in crucial subscription metrics. 2022 was an excellent year for Heska (NASDAQ:HSKA), with a solid performance in premium chemistry analyzer placements, up 28% in the fourth quarter year-over-year.

  1. Norbrook

Annual Revenue in 2022 (Million USD): 281

Norbrook, a leading global provider of veterinary pharmaceuticals, enhances the health of farm and companion animals through growth and innovation. The company aims to provide a balanced portfolio of products to its customers and end users, focusing on developing new veterinary products, being the first generic to market where possible, and differentiating its products through features and benefits.

  1. OuroFino

Annual Revenue in 2022 (Million USD): 340.87

Ourofino, a Brazilian veterinary pharmaceutical company, develops, produces, and sells veterinary drugs, vaccines, and other veterinary products for production and companion animals. In 2022, Ourofino’s net revenue exceeded R$ 1 billion, a 15% increase over 2021. EBITDA reached R$ 207.2 million, a 20.1% increase over 2021.

  1. Neogen Corp (NASDAQ:NEOG)

Annual Revenue in 2022 (Million USD): 527

Neogen Corp (NASDAQ:NEOG) experienced higher-than-normal input cost inflation in fiscal 2023, impacting operating results. While pricing actions mitigated some inflationary pressures, ongoing inflation could impact customer purchasing decisions and order patterns in fiscal 2024, albeit at a decreasing rate.

  1. Vetoquinol

Annual Revenue in 2022 (Million USD): 570

In 2022, Vetoquinol reported sales of €540m and net income of €63m from farm and pet animal healthcare products. Vetoquinol adopted its new strategic plan in 2022, setting its direction and roadmap for the next five years.

  1. Eco Animal Health

Annual Revenue in 2022 (Million USD): 82.19

Eco Animal Health Group plc is a UK-based animal health company that develops, registers, and markets pharmaceutical products for global markets. Its patented drug, Aivlosin, is a macrolide antibiotic for treating respiratory and enteric diseases in pigs and poultry. The company also offers generic endectocides and other antiparasitic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic.

  1. Phibro Animal Health Corp (NASDAQ:PAHC)

Annual Revenue in 2022 (Million USD): 942

Phibro Animal Health Corp’s (NASDAQ:PAHC) net sales increased 5% to $244.6 million in Q4 2022, while net income decreased 59% to $7.2 million. Despite the decline in net income, Phibro’s sales growth of more than 20% in 2022 put it in the top tier of animal health companies.

  1. Orion

Annual Revenue in 2022 (Million USD): 1,412 

In 2023, net sales of Orion are expected to be slightly higher than in 2022, excluding EUR 228m ODM-208 upfront payment (2022 net sales without ODM-208 upfront payment: EUR 1,113m).

  1. IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Annual Revenue in 2022 (Million USD): 3,367

IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported strong financial results for Q2 of 2023, with revenue up 10% reported and 10% organic to $1.07 billion.

Click to continue reading and see the Top 5 Animal Health Companies in the World.

Suggested Articles:

Disclosure. None. Top 20 Animal Health Companies in the World is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…